Emerging Therapies, Novel Mechanisms, and New Hope in the Treatment of PAH
| Overview / Abstract: |
The treatment landscape of pulmonary arterial hypertension (PAH) is poised to change dramatically in the near future. Designed with your questions in mind, this digital FAQ index offers succinct and relevant information for all practicing pulmonology and cardiology learners. What are some of the emerging therapies for PAH, and how do they differ from current treatment options? Which emerging therapies may be disease modifying? What clinical trial evidence is there for the treatments being investigated? What are the clinical implications of emerging therapies for the management of patients with PAH? Start the activity to find out the answers to these questions and more! |
|
Expiration |
Jun 30, 2024 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
|
Credits / Hours |
0.75 AMA PRA Category 1 Credit(s)™ |
|
Accreditation |
ACCME |
|
Presenters / Authors / Faculty |
John Ryan, MD, MB, BCH, BAO |
|
Sponsors / Supporters / Grant Providers |
Supported by an educational grant from Merck & Co., Inc. |
|
Keywords / Search Terms |
ACHL CME, Merck, Ryan, FAQ, pulmonary arterial hypertension, PAH, group 1 pulmonary hypertension, pulmonary hypertension, sotatercept, imatinib, seralutinib, AV-101, CS1, rodatristat, rodatristat ethyl, KER-012, MK-5475, mechanism of action, MOA, emerging therapies, disease-modifying, pulmonology, cardiology, patient outcomes, phosphodiesterase-5 inhibitors, PDE5I, prostacyclin, soluble guanylate cyclase stimulators, sGC Free CE CME |
|